In recent trading session, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) saw 10.34 million shares changing hands at last check today with its beta currently measuring 0.54. Company’s recent per share price level of $22.95 trading at $5.35 or 30.43% at last check today assigns it a market valuation of $3.84B. That most recent trading price of ACAD’s stock is at a premium of 9.89% from its 52-week high price of $20.68 and is indicating a premium of 41.61% from its 52-week low price of $13.40.
For Acadia Pharmaceuticals Inc (ACAD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.95. Splitting up the data highlights that, out of 16 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 14 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
Upright in the green today for gaining 30.43%, in the last five days ACAD remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $22.95 price level, adding 8.38% to its value on the day. Acadia Pharmaceuticals Inc’s shares saw a change of 25.10% in year-to-date performance and have moved 31.62% in past 5-day. Acadia Pharmaceuticals Inc (NASDAQ:ACAD) showed a performance of 57.55% in past 30-days.
Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a fall of -9.29% to its recent value today. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would jump 12.85% in reaching the projected high whereas dropping to the targeted low would mean a gain of 12.85% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -61.59% while estimates for its earnings growth in next 5 years are of 1.02%.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s Major holders
BAKER BROS. ADVISORS LP is the top institutional holder at ACAD for having 42.88 million shares of worth $696.77 million. And as of 2024-06-30, it was holding 25.9001 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 13.71 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2827 of outstanding shares, having a total worth of $222.82 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 7.61 shares of worth $173.13 million or 4.55% of the total outstanding shares. The later fund manager was in possession of 3.85 shares on Dec 31, 2024 , making its stake of worth around $87.52 million in the company or a holder of 2.30% of company’s stock.
